Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

, INVA

Innoviva

$10.91

-0.15 (-1.36%)

05:39
11/21/16
11/21
05:39
11/21/16
05:39

GSK, Innoviva files regulatory submission in U.S. for closed triple combination

GlaxoSmithKline (GSK) and Innoviva (INVA) announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol, or FF/UMEC/VI 100/62.5/25 mcg, for patients with chronic obstructive pulmonary disease, or COPD. This follows the announcement earlier this year of plans to bring forward the timing of the US filing from the first half of 2018. The closed triple combination therapy comprises three medicines: fluticasone furoate, an inhaled corticosteroid, or ICS, umeclidinium, a long-acting muscarinic antagonist, or LAMA, and vilanterol, a long-acting beta2-adrenergic agonist, or LABA, delivered once-daily in GSK's Ellipta dry powder inhaler. The U.S. regulatory submission of the closed triple therapy comprises a New Drug Application for the maintenance treatment of patients with COPD, including chronic bronchitis and emphysema. It is based on data from the closed triple combination therapy development programme, as well as data from studies with FF, UMEC and VI either alone or in combination.

GSK

GlaxoSmithKline

$38.11

-0.34 (-0.88%)

INVA

Innoviva

$10.91

-0.15 (-1.36%)

  • 29

    Nov

GSK GlaxoSmithKline
$38.11

-0.34 (-0.88%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
INVA Innoviva
$10.91

-0.15 (-1.36%)

10/31/16
COWN
10/31/16
UPGRADE
Target $15
COWN
Outperform
Innoviva upgraded to Outperform from Market Perform at Cowen
Cowen analyst Tyler Van Buren upgraded Innoviva to Outperform and raised its price target to $15 from $13 citing valuation discount and said the commercial prospects for Breo and Anoro remain stronger than ever heading into next year.

TODAY'S FREE FLY STORIES

$DJT

DJ Transportation Average

08:21
06/27/17
06/27
08:21
06/27/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$32.95

0.34 (1.04%)

, XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

08:20
06/27/17
06/27
08:20
06/27/17
08:20
Hot Stocks
Teva, Xenon says phase 2 study of topical TV-45070 did not meet primary endpoint »

Teva Pharmaceutical…

TEVA

Teva

$32.95

0.34 (1.04%)

XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

RICE

Rice Energy

$26.42

0.77 (3.00%)

08:20
06/27/17
06/27
08:20
06/27/17
08:20
Downgrade
Rice Energy rating change  »

Rice Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:20
06/27/17
06/27
08:20
06/27/17
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:20
06/27/17
06/27
08:20
06/27/17
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$169.98

0.86 (0.51%)

08:20
06/27/17
06/27
08:20
06/27/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:20
06/27/17
06/27
08:20
06/27/17
08:20
General news
Fedspeak from Chair Yellen is atop the roster »

Fedspeak from Chair…

XLK

Technology Select Sector SPDR

$56.00

-0.3 (-0.53%)

08:19
06/27/17
06/27
08:19
06/27/17
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$64.24

-0.14 (-0.22%)

08:19
06/27/17
06/27
08:19
06/27/17
08:19
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$89.84

0.32 (0.36%)

08:19
06/27/17
06/27
08:19
06/27/17
08:19
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$54.01

0.16 (0.30%)

08:19
06/27/17
06/27
08:19
06/27/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRX

Agile Therapeutics

$3.80

-0.04 (-1.04%)

08:19
06/27/17
06/27
08:19
06/27/17
08:19
Hot Stocks
Agile Therapeutics resubmits NDA for Twirla contraceptive patch »

Agile Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$53.57

0.36 (0.68%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$39.59

0.09 (0.23%)

, CHTR

Charter

$332.65

1.85 (0.56%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Technical Analysis
Technical View: Sprint rallies as it enters deal talks with Charter, Comcast »

The stock was last up…

CMCSA

Comcast

$39.59

0.09 (0.23%)

CHTR

Charter

$332.65

1.85 (0.56%)

S

Sprint

$8.01

-0.04 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 03

    Aug

XLP

Consumer Staples Sector SPDR

$55.71

0.22 (0.40%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$32.95

0.34 (1.04%)

, XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Hot Stocks
Breaking Hot Stocks news story on Teva, Xenon Pharmaceuticals »

Teva, Xenon says phase 2…

TEVA

Teva

$32.95

0.34 (1.04%)

XENE

Xenon Pharmaceuticals

$3.80

-0.3 (-7.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

XLV

Health Care Select Sector SPDR

$80.39

-0.08 (-0.10%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$141.08

0.17 (0.12%)

08:18
06/27/17
06/27
08:18
06/27/17
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$213.87

0.13 (0.06%)

08:17
06/27/17
06/27
08:17
06/27/17
08:17
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$243.29

0.16 (0.07%)

08:17
06/27/17
06/27
08:17
06/27/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$27.62

0.69 (2.56%)

, FOXA

21st Century Fox

$28.04

0.85 (3.13%)

08:17
06/27/17
06/27
08:17
06/27/17
08:17
Hot Stocks
21st Century Fox gets clearance from Republic of Ireland Minister for Sky deal »

21st Century Fox (FOX,…

FOX

21st Century Fox

$27.62

0.69 (2.56%)

FOXA

21st Century Fox

$28.04

0.85 (3.13%)

SKYAY

Sky

$49.20

0.2 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$24.02

0.13 (0.54%)

08:17
06/27/17
06/27
08:17
06/27/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMH

Market Vectors Semiconductor

$85.34

-0.33 (-0.39%)

08:16
06/27/17
06/27
08:16
06/27/17
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$90.66

-0.26 (-0.29%)

, PANW

Palo Alto Networks

$137.11

-1.3 (-0.94%)

08:16
06/27/17
06/27
08:16
06/27/17
08:16
Conference/Events
Maxim to hold a bus tour »

3rd Annual Silicon Valley…

VMW

VMware

$90.66

-0.26 (-0.29%)

PANW

Palo Alto Networks

$137.11

-1.3 (-0.94%)

NTAP

NetApp

$40.29

0.42 (1.05%)

PSTG

Pure Storage

$13.34

-0.15 (-1.11%)

SPLK

Splunk

$57.82

-0.61 (-1.04%)

HPE

HP Enterprise

$16.81

-0.04 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

QQQ

PowerShares QQQ Trust

$140.58

-0.66 (-0.47%)

08:16
06/27/17
06/27
08:16
06/27/17
08:16
Technical Analysis
PowerShares QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.